Spero Therapeutics, Inc.
SPRO
$2.26
$0.2411.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 61.19M | 66.80M | 40.55M | 48.58M | 44.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.19M | 66.80M | 40.55M | 48.58M | 44.58M |
| Cost of Revenue | -5.11M | 5.59M | 61.71M | 79.98M | 93.03M |
| Gross Profit | 107.59M | 102.51M | -21.16M | -31.40M | -48.45M |
| SG&A Expenses | 19.24M | 21.18M | 23.93M | 24.96M | 24.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.01M | 59.64M | 85.64M | 104.93M | 117.64M |
| Operating Income | 14.18M | 7.16M | -45.09M | -56.36M | -73.06M |
| Income Before Tax | 15.50M | 8.83M | -43.55M | -53.60M | -69.76M |
| Income Tax Expenses | 261.00K | 261.00K | 290.00K | 0.00 | 0.00 |
| Earnings from Continuing Operations | 15.24 | 8.57 | -43.84 | -53.60 | -69.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.24M | 8.57M | -43.84M | -53.60M | -69.76M |
| EBIT | 14.18M | 7.16M | -45.09M | -56.36M | -73.06M |
| EBITDA | 21.72M | 7.16M | -45.09M | -56.36M | -73.06M |
| EPS Basic | 0.28 | 0.15 | -0.79 | -0.98 | -1.28 |
| Normalized Basic EPS | 0.18 | 0.11 | -0.47 | -0.60 | -0.79 |
| EPS Diluted | 0.25 | 0.12 | -0.80 | -0.98 | -1.28 |
| Normalized Diluted EPS | 0.16 | 0.09 | -0.47 | -0.60 | -0.79 |
| Average Basic Shares Outstanding | 225.61M | 223.70M | 222.22M | 220.07M | 218.00M |
| Average Diluted Shares Outstanding | 228.96M | 227.05M | 222.22M | 220.07M | 218.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |